Company · NTRA
Natera, Inc.
Nasdaq's symbol directory lists NTRA on Nasdaq as “Natera, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders sold on 75 occasions ($160.7M); 32 planned-sale notices; 3 filings by holders of 5% or more; 1 company report (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 27, No. 26
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Rabinowitz Matthew, EXECUTIVE CHAIRMAN sold $95.3M
- Sheena Jonathan sold $19.6M
- RABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $14.5M
- Moshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $11.8M
- Chapman Steven Leonard, CEO AND PRESIDENT sold $7.3M
- ROSENMAN HERM sold $4.1M
- Brophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $4.0M
- Fesko John, PRESIDENT, CHIEF BUS. OFFICER sold $3.4M
- Chapman Rowan E sold $680K
Every trade (75)
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $184K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $1.6M
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $1.4M
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $299K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $136K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $130K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $121K
- SELLSheena Jonathan sold $45K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $811K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $1.5M
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $1.0M
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $495K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $413K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $383K
- SELLSheena Jonathan sold $80K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $919K
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $698K
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $410K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $359K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $317K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $317K
- SELLSheena Jonathan sold $118K
- SELLSheena Jonathan sold $1.3M
- SELLSheena Jonathan sold $604K
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $20.1M
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $1.2M
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $526K
- SELLSheena Jonathan sold $7.0M
- SELLSheena Jonathan sold $1.1M
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $18.1M
- SELLSheena Jonathan sold $2.1M
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $16.7M
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $16.4M
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $5.0M
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $962K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $545K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $2.1M
- SELLSheena Jonathan sold $2.0M
- SELLSheena Jonathan sold $2.9M
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $642K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $131K
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $906K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $819K
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $196K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $90K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $85K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $79K
- SELLSheena Jonathan sold $29K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $465K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $910K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $614K
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $306K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $255K
- SELLFesko John, PRESIDENT, CHIEF BUS. OFFICER sold $237K
- SELLSheena Jonathan sold $49K
- SELLChapman Steven Leonard, CEO AND PRESIDENT sold $570K
- SELLRabinowitz Matthew, EXECUTIVE CHAIRMAN sold $448K
- SELLMoshkevich Solomon, PRESIDENT, CLINICALDIAGNOSTICS sold $263K
- SELLRABINOWITZ DANIEL, SEC. AND CHIEF LEGAL OFFICER sold $230K
- SELLBrophy Michael Burkes, CHIEF FINANCIAL OFFICER sold $204K
Showing the latest 60 of 75.
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- MICHAEL BROPHY $178K
- SOLOMON MOSHKEVICH $1.2M
- STEVEN L CHAPMAN $1.2M
- STEVEN CHAPMAN $374K
- MATTHEW RABINOWITZ $299K
- SOLOMON MOSHKEVICH $168K
- DANIEL RABINOWITZ $137K
- MICHAEL BROPHY $130K
- JOHN FESKO $121K
- JONATHAN SHEENA $45K
- MICHAEL BROPHY $831K
- STEVEN CHAPMAN $1.4M
- MICHAEL BROPHY $502K
- SOLOMON MOSHKEVICH $487K
- MICHAEL BROPHY $484K
- DANIEL RABINOWITZ $406K
- JOHN FESKO $377K
- JONATHAN SHEENA $78K
- STEVEN CHAPMAN $905K
- MATTHEW RABINOWITZ $687K
- SOLOMON MOSHKEVICH $404K
- DANIEL RABINOWITZ $353K
- MICHAEL BROPHY $312K
- JOHN FESKO $312K
- JONATHAN SHEENA $116K
- Sheena Jonathan $3.9M
- MATTHEW RABINOWITZ $19.7M
- SOLOMON MOSHKEVICH $1.2M
- STEVEN L CHAPMAN $526K
- Sheena Jonathan $8.2M
- TINKERBELLE II TR U/A DTD 10/22/2021 $700K
- MATTHEW RABINOWITZ $65.2M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- FMR LLC 10.5%
- FMR LLC 9.5%
- T. Rowe Price Associates, Inc. 6.3%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Nov 5, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.